Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Open-Label Study in Diabetic Foot Ulcers (DFU), to Evaluate Safety of 0.03% DSC127 Topical Gel in Chronic Use (STRIDE 5)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01840085
Recruitment Status : Terminated
First Posted : April 25, 2013
Last Update Posted : December 12, 2017
Information provided by (Responsible Party):
Integra LifeSciences Corporation

Brief Summary:
To evaluate the safety of topical 0.03% DSC127 Gel when used for one or more continuous treatment periods on a chronic Wagner Grade 1 or 2 foot ulcer(target ulcer) or multiple ulcers in diabetic subjects. The maximum duration of any treatment period is 24 weeks.

Condition or disease Intervention/treatment Phase
Diabetic Foot Ulcer Drug: 0.03% DSC127 topical gel Phase 3

Detailed Description:

All eligible subjects enrolled will begin daily Treatment with topical 0.03% DSC127 gel until complete wound closure (defined as skin re-epithelialization without drainage or dressing requirement) or 24 weeks, whichever occurs first.

If a patient has multiple ulcers on one foot, all may be treated, within the maximum of 24 weeks. If the ulcer does not heal, after a wash out period of 1 week, a new treatment period of up to 24 weeks may be initiated. Ulcer may be retreated if it recurs or if a new ulcer develops that meets study criteria.

For the entire duration of each treatment period the standard of care for DFU will be maintained.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 261 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-Label Phase III Clinical Trial to Evaluate the Safety of 0.03% DSC127 Gel in Chronic Use for Treating Diabetic Foot Ulcers ("DFU")
Study Start Date : December 2015
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 0.03% DSC127 topical gel Drug: 0.03% DSC127 topical gel

Primary Outcome Measures :
  1. The proportion of all subjects reporting Adverse Events and Serious Adverse Events related to study treatment [ Time Frame: 2.5yrs ]

Other Outcome Measures:
  1. Changes from baseline in laboratory evaluations (clinically significant changes) [ Time Frame: 2.5yrs ]
  2. Proportion of all subjects treated and terminating prematurely due to adverse events related to study treatment. [ Time Frame: 2.5yrs ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female ambulatory subjects who are at least 18 years of age at screening
  2. Have at least one ulcer:

    1. chronic ( present >1month)
    2. Wagner Grade 1 or Grade 2 ulcer (i.e. Partial- or full- thickness and not involving bone, tendon or capsule (probing to tendon or capsule) and/or penetrating to tendon or capsule.)
    3. with no sign of infection or osteomyelitis, and
    4. is located below the malleolus.
  3. Have an ABI > 0.7, or have a TcPO2 > 40 mm Hg or great toe systolic pressure > 50 mmHg to ensure healing potential.
  4. Have Type I or Type II diabetes under metabolic control as confirmed by glycosylated hemoglobin (HbA1c) of ≤ 14%, obtained at enrollment or within 30 days prior to study enrollment.
  5. Female subjects of child-bearing potential must have a negative pregnancy test at the time of enrollment and at the initiation of each study treatment period.
  6. Female subjects of child-bearing potential must be willing to use a medically acceptable method of birth control, such as Essure®, hormonal contraception (oral pills, implantable device or skin patch), intrauterine device, tubal ligation, double barrier, or abstinence during the treatment periods of study participation.
  7. Ability and willingness to understand and comply with study procedures and to give written informed consent prior to enrollment in the study or initiation of study procedures

Exclusion Criteria:

  1. Has a known hypersensitivity to any of the study medication components.
  2. Exposure to any investigational product within 30 days of entry into study.
  3. Has active malignant disease of any kind (with the exception of basal cell carcinoma). A subject, who has had a malignant disease in the past, was treated and is currently disease-free, may be considered for study entry. Disease-free is defined as in remission for at least 5 years.
  4. Chronic liver dysfunction evidenced by transaminase levels > 2.5 times higher than the upper level of normal on two occasions.
  5. Has a history of additional risk factors for TdP (eg. heart failure, hypokalemia, family history of Long QT Syndrome) or taking medication which are known to prolong QT/QTc (Appendix G)
  6. Receiving hemodialysis or chronic ambulatory peritoneal dialysis (CAPD) therapy.
  7. Prior radiation therapy of the foot with the ulcer under study.
  8. Current use of systemic corticosteroids or immunosuppressants within 8 weeks prior to enrollment into the study
  9. Sickle-cell anemia, Raynaud's or other peripheral vascular disease.
  10. Subjects receiving a biologic agent to include growth factors and skin equivalents (Regranex, Apligraft, or Dermagraft) in the 7 days prior to exposure to DSC127.
  11. Subject who, in the opinion of the investigator, has uncontrolled hypertension
  12. Subject has an ulcer which is determined to be clinically infected and requires antimicrobials or agents known to affect wound healing or has been taking systemic antibiotics for more than 7 days for any reason. (Subjects with infection at the initial visit of the Screening Period can be re-screened three weeks later after a single course of antibiotic therapy (occurring concurrently - within three weeks of the initial visit, the antibiotic treatment must have completed and some washout (7 days) must have elapsed); if after that time infection is still present, the subject will be excluded.)
  13. Subjects who, in the opinion of the investigator, have clinically significant anemia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01840085

Show Show 21 study locations
Sponsors and Collaborators
Integra LifeSciences Corporation
Layout table for investigator information
Study Director: John Caminis, MD Integra LifeSciences Corporation
Layout table for additonal information
Responsible Party: Integra LifeSciences Corporation Identifier: NCT01840085    
Other Study ID Numbers: DSC127-2012-05
First Posted: April 25, 2013    Key Record Dates
Last Update Posted: December 12, 2017
Last Verified: December 2017
Keywords provided by Integra LifeSciences Corporation:
Diabetic foot ulcer
plantar neuropathic ulcer
plantar neuroischemic ulcer
Wagner Grade 1 or Grade 2 DFU
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetic Foot
Foot Ulcer
Pathologic Processes
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies
Foot Diseases